Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer speed toward approvals

Roche’s immuno-oncology rivals are hurtling toward a showdown in previously untreated kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.